Invesco Ltd. (IVZ) Stock Price Today
Aura AI Summary
Key Stats
- $13.13BMarket Cap
- -Volume
- FinancialsSector
- $30.3052W High
- $19.9252W Low
- -Typical Hold Time
- $23.38BEnterprise Value
- 2.9%Div Yield
- -Trading Activity
Track Invesco Ltd. (IVZ) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Invesco Ltd. has traded between a low of $19.92 and a high of $30.3, highlighting its annual price range. Buy and sell Invesco Ltd. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Most Recent News
US chip stocks fall on fears over new Chinese Kimi K3 model, despite strong earnings from TSMC and ASML.
US semiconductor stocks dropped sharply after the introduction of a new Chinese chip model called Kimi K3, which rattled investors despite strong earnings and raised guidance from major players like TSMC and ASML. The SOXX ETF fell 1.5%, reflecting b...
S&P 500 falls 1.6% as investors shift from growth to value amid inflation and geopolitical concerns
Last week, the S&P 500 dropped 1.6% as investors moved away from large-cap growth stocks toward value and defensive sectors. Energy and commodities outperformed, while technology and momentum stocks lagged due to renewed geopolitical tensions and inf...
Medicus Pharma's redesigned Teverelix study gets FDA and IRB approval, cutting costs and patient numbers significantly.
Medicus Pharma announced that its redesigned clinical study protocol for Teverelix, a next-generation hormone antagonist for men's health, has received approval from the Institutional Review Board and conditional acceptance from the FDA. The revised ...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.